Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease

Exclusion Criteria

• •Any medical or neurological condition (other than Alzheimer's Disease) that might be a contributing cause of the participant's cognitive impairment.
• •Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of consciousness in the past 1 year.
• •Clinically significant psychiatric illness in past 6 months.
• •Seizure in the past 3 years.
• •Poorly controlled diabetes mellitus.
• •History of unstable angina, myocardial infarction, chronic heart failure, or clinical significant conduction abnormalities within 1 year prior to Screening.
• •Indication of impaired renal or liver function.
• •Have human immunodeficiency virus (HIV) infection.
• •Have a significant systematic illness or infection in past 30 days.
• •Brain MRI showing evidence of acute or sub-acute micro or macrohemorrhage, greater than 4 microhemorrhages, cortical infarct or greater than one 1 lunar infarct.
• •Any contraindications to brain MRI or positron emission tomography (PET) scans.
• •Negative positron emission tomography (PET) scan with any amyloid-targeting ligand within 48 weeks of Screening.
• •Clinically significant 12-lead electrocardiogram (ECG) abnormalities.
• •Alcohol or substance abuse in past 1 year.
• •Taking blood thinners (except for aspirin at a prophylactic dose or less)
• •Have changes in medications or doses of medication in past 4 weeks.